Kaken Pharmaceutical Co Ltd (4521) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Business description - A detailed description of the company’s operations and business divisions.
Corporate strategy - Analyst’s summarization of the company’s business strategy.
SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
Company history - Progression of key events associated with the company.
Major products and services - A list of major products, services and brands of the company.
Key competitors - A list of key competitors to the company.
Key employees - A list of the key executives of the company.
Executive biographies - A brief summary of the executives’ employment history.
Key operational heads - A list of personnel heading key departments/functions.
Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Kaken Pharmaceutical Co Ltd (Kaken) is a pharmaceutical company. It develops and markets prescription pharmaceutical drugs, agrochemicals, medical equipment and products related to animal health. The company offers solutions in the fields of orthopedics, dermatology, inflammation, allergy, fungal infections and pain relief. Kaken offers fungicides, rice herbicides, feed additives for chicken and veterinary drugs. The company also offers real estate rental services. The company's products focus on new drugs, particularly in the fields of dermatology and orthopedics, and a natural pesticide called Polyoxin. The company's products cater to healthcare providers and agricultural industries. It markets products through license and distribution agreements with companies in the US, Canada, Taiwan, China, South Korea, Israel and Jordan and operates sales offices in various places in Japan. Kaken is headquartered in Bunkyo-ku, Tokyo, Japan.
Kaken Pharmaceutical Co Ltd Key Recent Developments
Nov 13, 2025: Numab Therapeutics and Kaken Pharmaceutical Announce Licensing and Co-development Agreement for NM81 in Inflammatory Bowel Disease
Nov 10, 2025: Consolidated Financial Results for the Six-Months Period of Fiscal 2025 (Six-Month Period Ended September 30, 2025)
Aug 07, 2025: Astria Therapeutics licenses navenibart rights to Kaken for HAE
Aug 07, 2025: Kaken Pharma : Consolidated Financial Results for the Three Months Period of Fiscal 2025 (Three Month Period Ended June 30, 2025)
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Section 1 - About the Company
Kaken Pharmaceutical Co Ltd - Key Facts
Kaken Pharmaceutical Co Ltd - Key Employees
Kaken Pharmaceutical Co Ltd - Key Employee Biographies
Kaken Pharmaceutical Co Ltd - Major Products and Services
Kaken Pharmaceutical Co Ltd - History
Kaken Pharmaceutical Co Ltd - Company Statement
Kaken Pharmaceutical Co Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Affiliate
Section 2 - Company Analysis
Company Overview
Kaken Pharmaceutical Co Ltd - Business Description
Business Segment: Pharmaceutical Industry
Overview
Performance
Business Segment: Real Estate Business
Overview
Performance
Geographical Segment: Asia
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Japan
Performance
Geographical Segment: North America
Performance
Geographical Segment: Others
Performance
R&D Overview
Kaken Pharmaceutical Co Ltd - Corporate Strategy
Kaken Pharmaceutical Co Ltd - SWOT Analysis
SWOT Analysis - Overview
Kaken Pharmaceutical Co Ltd - Strengths
Kaken Pharmaceutical Co Ltd - Weaknesses
Kaken Pharmaceutical Co Ltd - Opportunities
Kaken Pharmaceutical Co Ltd - Threats
Kaken Pharmaceutical Co Ltd - Key Competitors
Section 3 - Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Kaken Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Year, 2019 to YTD 2025
Kaken Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
Kaken Pharmaceutical Co Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
Nov 13, 2025: Numab Therapeutics and Kaken Pharmaceutical Announce Licensing and Co-development Agreement for NM81 in Inflammatory Bowel Disease
Nov 10, 2025: Consolidated Financial Results for the Six-Months Period of Fiscal 2025 (Six-Month Period Ended September 30, 2025)
Aug 07, 2025: Astria Therapeutics licenses navenibart rights to Kaken for HAE
Aug 07, 2025: Kaken Pharma : Consolidated Financial Results for the Three Months Period of Fiscal 2025 (Three Month Period Ended June 30, 2025)
May 12, 2025: Kaken Pharma : Consolidated Financial Results for the Fiscal Year Ended March 31, 2025
Apr 08, 2025: KalVista licenses commercialisation rights for HAE to Kaken in Japan
Mar 25, 2025: Alumis and Kaken sign agreement in Japan to develop ESK-001
Feb 06, 2025: Kaken Pharma : Consolidated Financial Results for the Nine-Months Period of Fiscal 2024 (Nine-Month Period Ended December 31, 2024)
Nov 08, 2024: Kaken Pharma : Consolidated Financial Results for the Six-Months Period of Fiscal 2024
Aug 07, 2024: Kaken Pharma : Consolidated Financial Results for the First Quarter of Fiscal 2024
Section 6 - Appendix
Methodology
Ratio Definitions
About the Analyst
Contact the Publisher
Disclaimer
List of Tables
Kaken Pharmaceutical Co Ltd, Key Facts
Kaken Pharmaceutical Co Ltd, Key Employees
Kaken Pharmaceutical Co Ltd, Key Employee Biographies
Kaken Pharmaceutical Co Ltd, Major Products and Services
Kaken Pharmaceutical Co Ltd, History
Kaken Pharmaceutical Co Ltd, Other Locations
Kaken Pharmaceutical Co Ltd, Subsidiaries
Kaken Pharmaceutical Co Ltd, Affiliate
Kaken Pharmaceutical Co Ltd, Key Competitors
Kaken Pharmaceutical Co Ltd, Ratios based on current share price
Kaken Pharmaceutical Co Ltd, Annual Ratios
Kaken Pharmaceutical Co Ltd, Interim Ratios
Kaken Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Year, 2019 to YTD 2025
Kaken Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
Kaken Pharmaceutical Co Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Kaken Pharmaceutical Co Ltd, Performance Chart (2021 - 2025)
Kaken Pharmaceutical Co Ltd, Ratio Charts
Kaken Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Year, 2019 to YTD 2025
Kaken Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025
This product is a company SWOT Analysis. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a company SWOT Analysis. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a company SWOT Analysis. This is a site license, allowing all users within a given geographical location of your organization access to the product. The product is a PDF.
The sample excerpt is provided to help you make an informed purchasing decision. It is not intended to serve as free content or replace a full report. To ensure the sample aligns with your specific needs, our team will contact you to better understand your requirements.
An error occurred while sending the message. Should this issue persist, email us at help@researchandmarkets.net
This report can be tailored to focus on a specific country, region, continent, or provide global coverage. Please indicate your regions of interest and share any additional questions you may have. Our team strives to respond to all inquiries within the same business day.
An error occurred while sending the message. Should this issue persist, email us at help@researchandmarkets.net